1
|
Kubo T, Sunami K, Koyama T, Kitami M, Fujiwara Y, Kondo S, Yonemori K, Noguchi E, Morizane C, Goto Y, Maejima A, Iwasa S, Hamaguchi T, Kawai A, Namikawa K, Arakawa A, Sugiyama M, Ohno M, Yoshida T, Hiraoka N, Yoshida A, Yoshida M, Nishino T, Furukawa E, Narushima D, Nagai M, Kato M, Ichikawa H, Fujiwara Y, Kohno T, Yamamoto N. The impact of rare cancer and early-line treatments on the benefit of comprehensive genome profiling-based precision oncology. ESMO Open 2024; 9:102981. [PMID: 38613908 PMCID: PMC11033064 DOI: 10.1016/j.esmoop.2024.102981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 03/04/2024] [Accepted: 03/04/2024] [Indexed: 04/15/2024] Open
Abstract
BACKGROUND Comprehensive genome profiling (CGP) serves as a guide for suitable genomically matched therapies for patients with cancer. However, little is known about the impact of the timing and types of cancer on the therapeutic benefit of CGP. MATERIALS AND METHODS A single hospital-based pan-cancer prospective study (TOP-GEAR; UMIN000011141) was conducted to examine the benefit of CGP with respect to the timing and types of cancer. Patients with advanced solid tumors (>30 types) who either progressed with or without standard treatments were genotyped using a single CGP test. The subjects were followed up for a median duration of 590 days to examine therapeutic response, using progression-free survival (PFS), PFS ratio, and factors associated with therapeutic response. RESULTS Among the 507 patients, 62 (12.2%) received matched therapies with an overall response rate (ORR) of 32.3%. The PFS ratios (≥1.3) were observed in 46.3% (19/41) of the evaluated patients. The proportion of subjects receiving such therapies in the rare cancer cohort was lower than that in the non-rare cancer cohort (9.6% and 17.4%, respectively; P = 0.010). However, ORR of the rare cancer patients was higher than that in the non-rare cancer cohort (43.8% and 20.0%, respectively; P = 0.046). Moreover, ORR of matched therapies in the first or second line after receiving the CGP test was higher than that in the third or later lines (62.5% and 21.7%, respectively; P = 0.003). Rare cancer and early-line treatment were significantly and independently associated with ORR of matched therapies in multivariable analysis (P = 0.017 and 0.004, respectively). CONCLUSION Patients with rare cancer preferentially benefited from tumor mutation profiling by increasing the chances of therapeutic response to matched therapies. Early-line treatments after profiling increase the therapeutic benefit, irrespective of tumor types.
Collapse
Affiliation(s)
- T Kubo
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo; Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo
| | - K Sunami
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo; Division of Genome Biology, National Cancer Center Research Institute, Tokyo
| | - T Koyama
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo
| | - M Kitami
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo
| | - Y Fujiwara
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Aichi
| | - S Kondo
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo
| | - K Yonemori
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - E Noguchi
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - C Morizane
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo
| | - Y Goto
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo
| | - A Maejima
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo; Department of Urology, National Cancer Center Hospital, Tokyo
| | - S Iwasa
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo; Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo
| | - T Hamaguchi
- Department of Medical Oncology, Saitama Medical University International Medical Center, Saitama
| | - A Kawai
- Department of Musculoskeletal Oncology and Rehabilitation, National Cancer Center Hospital, Tokyo
| | - K Namikawa
- Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo
| | - A Arakawa
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo
| | - M Sugiyama
- Department of Pediatric Oncology, National Cancer Center Hospital, Tokyo
| | - M Ohno
- Department of Neurosurgery and Neuro-Oncology, National Cancer Center Hospital, Tokyo
| | - T Yoshida
- Department of Genetic Services and Medicine, National Cancer Center Hospital, Tokyo
| | - N Hiraoka
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - A Yoshida
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - M Yoshida
- Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo
| | - T Nishino
- Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo
| | - E Furukawa
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - D Narushima
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - M Nagai
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - M Kato
- Division of Bioinformatics, National Cancer Center Research Institute, Tokyo
| | - H Ichikawa
- Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo; Division of Translational Genomics, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - Y Fujiwara
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo
| | - T Kohno
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo; Division of Translational Genomics, National Cancer Center Exploratory Oncology Research & Clinical Trial Center, Tokyo, Japan
| | - N Yamamoto
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo.
| |
Collapse
|
2
|
Hattori T, Fujioka K, Nagai T, Kondo S, Kagami S, Hirayama M, Urushihara M. Intrarenal renin-angiotensin system activation and macrophage infiltrations in pediatric chronic glomerulonephritis. Pediatr Nephrol 2023; 38:3711-3719. [PMID: 37231123 PMCID: PMC10514104 DOI: 10.1007/s00467-023-06026-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/26/2022] [Revised: 04/21/2023] [Accepted: 04/25/2023] [Indexed: 05/27/2023]
Abstract
BACKGROUND The current study tested the hypothesis that urinary angiotensinogen (UAGT) and urinary monocyte chemoattractant protein-1 (UMCP-1) levels provide a specific index of intrarenal renin-angiotensin system (RAS) status and the degree of infiltration of macrophages associated with RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis. METHODS We measured baseline UAGT and UMCP-1 levels to examine the correlation between glomerular injury in 48 pediatric chronic glomerulonephritis patients before treatment. Furthermore, we performed immunohistochemical analysis of angiotensinogen (AGT) and CD68 in 27 pediatric chronic glomerulonephritis patients treated with RAS blockades and immunosuppressants for 2 years. Finally, we examined the effects of angiotensin II (Ang II) on monocyte chemoattractant protein-1 (MCP-1) expression in cultured human mesangial cells (MCs). RESULTS Baseline UAGT and UMCP-1 levels positively correlated with urinary protein levels, scores for mesangial hypercellularity, rate of crescentic formation, and expression levels of AGT and CD68 in renal tissues (p < 0.05). UAGT and UMCP-1 levels were significantly decreased after RAS blockade and immunosuppressant treatment (p < 0.01), which was accompanied by AGT and CD68 (p < 0.01), as well as the magnitude of glomerular injury. Cultured human MCs showed increased MCP-1 messenger ribonucleic acid and protein levels after Ang II treatment (p < 0.01). CONCLUSIONS The data indicates that UAGT and UMCP-1 are useful biomarkers of the degree of glomerular injury during RAS blockade and immunosuppressant treatment in pediatric patients with chronic glomerulonephritis.
Collapse
Affiliation(s)
- Tomoki Hattori
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan
- Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan
| | - Keisuke Fujioka
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan
| | - Takashi Nagai
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan
| | - Shoji Kagami
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan
| | - Masahiro Hirayama
- Department of Pediatrics, Mie University Graduate School of Medicine, Mie, Japan
| | - Maki Urushihara
- Department of Pediatrics, Tokushima University Graduate School of Biomedical Sciences, Kuramoto-cho 3-18-15, Tokushima, Tokushima, 770-8503, Japan.
| |
Collapse
|
3
|
Ono A, Mori K, Fukura S, Kondo S, Yokota N, Ishibashi H. A case of strangulated intestinal obstruction in which disease progression was recognized on ultrasonography: importance of "string-like structure". J Med Ultrason (2001) 2023; 50:459-460. [PMID: 37071256 DOI: 10.1007/s10396-023-01302-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 02/27/2023] [Indexed: 04/19/2023]
Affiliation(s)
- Akemi Ono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto-cho, Tokushima, Tokushima, 770-8539, Japan.
| | - Kazuhiro Mori
- Department of Pediatrics, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto-cho, Tokushima, Tokushima, 770-8539, Japan
| | - Shoko Fukura
- Department of Pediatrics, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto-cho, Tokushima, Tokushima, 770-8539, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto-cho, Tokushima, Tokushima, 770-8539, Japan
| | - Noriko Yokota
- Department of Pediatric Surgery and Pediatric Endoscopic Surgery, Tokushima University Hospital, Tokushima, Japan
| | - Hiroki Ishibashi
- Department of Pediatric Surgery and Pediatric Endoscopic Surgery, Tokushima University Hospital, Tokushima, Japan
| |
Collapse
|
4
|
Shichijo K, Fukura S, Takeuchi S, Tayama T, Ono A, Ichihara Y, Suga K, Sato H, Takechi A, Matsumoto S, Fujino S, Taniguchi T, Takahashi A, Watanabe T, Kondo S. A surge in respiratory syncytial virus infection-related hospitalizations associated with the COVID-19 pandemic: An observational study at pediatric emergency referral hospitals in Tokushima Prefecture. PLOS Glob Public Health 2023; 3:e0001974. [PMID: 37267243 DOI: 10.1371/journal.pgph.0001974] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Accepted: 05/11/2023] [Indexed: 06/04/2023]
Abstract
The outbreak of coronavirus disease (COVID-19) resulted in implementation of social distancing and other public health measures to control the spread of infection and improve prevention, resulting in a decrease in respiratory syncytial virus (RSV) and pediatric respiratory tract infection rates. However, there was a rapid and large re-emergence of RSV infection in Japan. Notably, we were faced with a difficult situation wherein there was a shortage of hospital beds. This study aimed to examine the epidemiological patterns of RSV-related hospitalizations among children before and after the COVID-19 pandemic onset at two pediatric emergency referral hospitals covering the entire Tokushima Prefecture. Data were extracted from electronic medical records of children hospitalized with RSV infection between January 1, 2018, and December 31, 2021. All patients meeting the eligibility criteria were included in this study. The rates of study outcomes were documented annually during 2018-2021 and compared between the 2018-2020 and 2021 periods. In 2020, there was no RSV infection outbreak. Hospitalizations at the peak week in 2021 were 2.2- and 2.8-fold higher than those in 2018 and 2019, respectively. Hospitalizations in 2021 were concentrated within a short period. In addition, there was a significant increase in hospitalizations among children aged 3-5 months and those older than 24 months. The high-flow nasal cannula (HFNC) use rate nearly doubled in 2021. A new pandemic in the future may cause an outbreak of RSV infection that can result in an intensive increase in the number of hospitalizations of pediatric patients requiring respiratory support, especially in infants aged <6 months. There is an urgent need to improve the preparedness of medical systems, particularly in terms of the number of inpatient beds and the immediate availability of HFNC.
Collapse
Affiliation(s)
- Koichi Shichijo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Shoko Fukura
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Shunsuke Takeuchi
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Takahiro Tayama
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Akemi Ono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Yuko Ichihara
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Kenichi Suga
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Hiroki Sato
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Atsumi Takechi
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Sonomi Matsumoto
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Shuji Fujino
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Takako Taniguchi
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Akiyoshi Takahashi
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Tsutomu Watanabe
- Department of Pediatrics, Tokushima Red Cross Hospital, Komatsushima, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| |
Collapse
|
5
|
Fukura S, Takei M, Takeuchi S, Tayama T, Ono A, Ichihara Y, Shichijo K, Suzuki Y, Mori K, Kondo S. A pediatric case of infliximab-resistant ulcerative colitis successfully treated using vedolizumab. J Med Invest 2023; 70:294-297. [PMID: 37164738 DOI: 10.2152/jmi.70.294] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Pediatric ulcerative colitis is likely to be more severe than adult ulcerative colitis. Failure to thrive should be considered during therapy. A 10-year-old boy was diagnosed with ulcerative colitis based on his clinical presentation and colonoscopy and biopsy results. The administration of 5-aminosalicylic acid and prednisolone resulted in remission ; however, the symptoms reappeared after the discontinuation of prednisolone. Then, infliximab was administered ; however, the patient was resistant to it and appeared to be dependent on prednisolone. Vedolizumab, a monoclonal antibody against ?4?7 integrin, was administered, which resulted in rapid remission. A steady decrease in prednisolone followed, and remission was maintained even after prednisolone discontinuation. Vedolizumab may be effective in pediatric patients with moderate-to-severe refractory ulcerative colitis. Vedolizumab prevents lymphocytes from binding to MAdCAM-1, which is selectively expressed in the gastrointestinal submucosa, leading to the mitigation of the systemic side effects of immunosuppression, such as infections. In Japan, vedolizumab use is not yet approved for use in children, but its effectiveness and safety in children is expected to be investigated in the future. J. Med. Invest. 70 : 294-297, February, 2023.
Collapse
Affiliation(s)
- Shoko Fukura
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Mikiko Takei
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
- Department of Pediatrics, Tokushima Municipal Hospital, Japan
| | - Shunsuke Takeuchi
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Takahiro Tayama
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Akemi Ono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Yuko Ichihara
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Koichi Shichijo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Yasuhiro Suzuki
- Department of Gastroenterology, Tokushima Prefectural Central Hospital, Japan
| | - Kazuhiro Mori
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Japan
| |
Collapse
|
6
|
Takei M, Suga K, Takeuchi S, Tayama T, Fujioka K, Ono A, Shono M, Shichijo K, Kosaka H, Kobayashi N, Kondo S. Osteoarticular infections at a pediatric emergency core hospital in Japan. J Med Invest 2023; 70:236-240. [PMID: 37164728 DOI: 10.2152/jmi.70.236] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
OBJECTIVES Osteomyelitis (OM) and septic arthritis (SA) in childhood might cause complications, sequelae, or even death if diagnosis and treatment are delayed. Here, we examined the outcomes of OM/SA at a pediatric emergency core hospital in Japan. METHODS This was a single-center, retrospective, observational cohort study at a pediatric emergency core hospital in Japan. Pediatric outpatients who underwent magnetic resonance imaging at the hospital in the period 2012?2020 were recruited. Primary outcomes were sequelae, recurrent symptoms, chronicity, and death. RESULTS Fifteen OM/SA patients (9 OM, 4 SA, 2 OM+SA) were recruited. The identified major pathogens included methicillin-susceptible Staphylococcus aureus (40.0 %, n=6) and methicillin-resistant S. aureus (13.3 %, n=2). Mean time from onset to first hospital visit, hospitalization, and initiation of effective antibiotics was 2 days, 3.9?±?1.8 days, and 4.9±2.2 days, respectively. All OM/SA patients recovered without complications or sequelae. CONCLUSIONS In this study, all patients with OM/SA showed a good prognosis. Despite the small sample size, this pilot study suggests that the pediatric emergency core system in Japan provides early treatment and a good prognosis for patients diagnosed with OM/SA. J. Med. Invest. 70 : 236-240, February, 2023.
Collapse
Affiliation(s)
- Mikiko Takei
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Kenichi Suga
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
- Department of Pediatrics, Tokushima University Hospital, Tokushima, Japan
| | - Shunsuke Takeuchi
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Takahiro Tayama
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Keisuke Fujioka
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Akemi Ono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Miki Shono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Koichi Shichijo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Hirofumi Kosaka
- Department of Orthopedics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Naoto Kobayashi
- Department of Radiology, Tokushima Prefectural Central Hospital, Tokushima, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Tokushima, Japan
| |
Collapse
|
7
|
Kondo S, Koyama T, Kawazoe A, Iwasa S, Yonemori K, Shitara K, Nakamura Y, Saori M, Yamamoto N, Sato J, Sahara T, Hayata N, Yamamuro S, Kimura T, Dutta L, Tamai T, Ikeda M. 401P A phase Ib study of E7386, a CREB-binding protein (CBP)/β-catenin interaction inhibitor, in combination with lenvatinib in patients (pts) with advanced solid tumors. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022] Open
|
8
|
Oishi Y, Tsujita H, Arai T, Sakai R, Sato S, Tanaka H, Ogura K, Masaki R, Kondo S, Tsukamoto S, Higuchi S, Sumida A, Matsumoto H, Shinke T. The vascular response to ultrathin biodegradable polymer sirolimus-eluting stent at 2-weeks and 1-year follow up in patients with ST-elevation myocardial infarction. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Recent clinical study suggests newer-generation drug-eluting stents (DES) that combine ultrathin strut and nano-coating with biodegradable polymers sirolimus-eluting stent (BP-SES) could improve long-term clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) over current generation DES. However, the details of vascular response in very early and chronic phase have not been systematically addressed.
Objective and method
We exploratory investigate early and chronic vascular response following BP-SES implantation in patients with STEMI to reveal mechanism of the favorable clinical outcomes in recent studies using frequency domain-optical coherence tomography (FD-OCT).
Consecutive twenty-four patients with STEMI who underwent FD-OCT after primary PCI and were eligible for follow-up FD-OCT at 2 weeks and 1 year after implantation were enrolled between June 2018 and August 2020.
OCT was performed immediately after PCI, at 2-weeks (2W) and 1-year (1Y) after the primary PCI. Struts were recorded as uncovered if any part was visibly exposed in the lumen or covered if a layer of tissue covered all reflecting surfaces. Struts of stents that are smaller than 3.0mm of diameter with more than 80μm between the center reflection and the adjacent vessel surface were recorded as malapposed. The reduction of atherothrombotic protrusion burden within the stent was also assessed.
Results
Twenty-four patients (age 64.9±11.4 years, male 83.3%) were enrolled.
The percentage of uncovered struts significantly decreased from post-PCI to 2W follow-up and from 2W follow-up to 1Y follow-up (62±20% post-PCI versus 27±11% at 2W follow up, p<0.0001 and 2W follow-up versus 3.3±3.3% at 1Y follow up, p<0.0001). Malapposed struts also decreased from post-PCI to 2W follow-up (4.1±3.6% post-PCI versus 1.5±2.2% at 2W follow-up, p<0.0001), but no significant difference was shown between 2W follow-up and 1Y follow-up (2W follow-up versus 1.0±2.3 at 1Y follow up, p=0.12). The average protrusion area of athero-thrombotic burden decreased (0.57±0.32 at post-PCI versus 0.42±0.22 mm2 at 2W follow up, p<0.0001) and its volume showed similar tendency (16.6±10.7 at post-PCI versus 12.9±8.23 mm3 at 2W follow up, p=0.0011). Thrombus was shown in all patients at post-PCI, but two patients (8.0%) showed it at 1Y follow-up.
Conclusion(s)
This study elucidated very early and chronic vascular responses following ultrathin strut BP-SES implantation in STEMI patients by FD-OCT. It showed resolution of athero-thrombotic materials in very early phase and favorable progression of strut coverage in very early and chronic phase.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- Y Oishi
- Showa University Hospital , Tokyo , Japan
| | - H Tsujita
- Showa University Hospital , Tokyo , Japan
| | - T Arai
- Showa University Hospital , Tokyo , Japan
| | - R Sakai
- Showa University Hospital , Tokyo , Japan
| | - S Sato
- Showa University Hospital , Tokyo , Japan
| | - H Tanaka
- Showa University Hospital , Tokyo , Japan
| | - K Ogura
- Showa University Hospital , Tokyo , Japan
| | - R Masaki
- Showa University Hospital , Tokyo , Japan
| | - S Kondo
- Showa University Hospital , Tokyo , Japan
| | | | - S Higuchi
- Showa University Hospital , Tokyo , Japan
| | - A Sumida
- Showa University Hospital , Tokyo , Japan
| | | | - T Shinke
- Showa University Hospital , Tokyo , Japan
| |
Collapse
|
9
|
Abstract
Antimicrobial peptides (AMPs) are key to defence against infection in plants and animals. Use of AMP mutations in Drosophila has now revealed that AMPs can additively or synergistically contribute to defence in vivo. However, these studies also revealed high specificity, wherein just one AMP contributes an outsized role in combatting a specific pathogen. Here, we show the Drosocin locus (CG10816) is more complex than previously described. In addition to its namesake peptide 'Drosocin', it encodes a second mature peptide from a precursor via furin cleavage. This peptide corresponds to the previously uncharacterized 'Immune-induced Molecule 7'. A polymorphism (Thr52Ala) in the Drosocin precursor protein previously masked the identification of this peptide, which we name 'Buletin'. Using mutations differently affecting Drosocin and Buletin, we show that only Drosocin contributes to Drosocin gene-mediated defence against Enterobacter cloacae. Strikingly, we observed that Buletin, but not Drosocin, contributes to the Drosocin gene-mediated defence against Providencia burhodogranariea, including an importance of the Thr52Ala polymorphism for survival. Our study reveals that the Drosocin gene encodes two prominent host defence peptides with different specificity against distinct pathogens. This finding emphasizes the complexity of the Drosophila humoral response and demonstrates how natural polymorphisms can affect host susceptibility.
Collapse
Affiliation(s)
- M. A. Hanson
- Global Health Institute, School of Life Science, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| | - S. Kondo
- Invertebrate Genetics Laboratory, Genetic Strains Research Center, National Institute of Genetics, Mishima, Japan
| | - B. Lemaitre
- Global Health Institute, School of Life Science, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
| |
Collapse
|
10
|
Tohgasaki T, Kondo S, Nishizawa S, Ishiwatari S, Sakurai T, Ishikawa S, Takeda A. Evaluation of elastin fibres in young and aged eyelids and abdominal skin using computational 3D structural analysis. Skin Health and Disease 2021; 1:e58. [PMID: 35663779 PMCID: PMC9060010 DOI: 10.1002/ski2.58] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/21/2021] [Revised: 06/08/2021] [Accepted: 06/12/2021] [Indexed: 11/17/2022]
Abstract
Background Aging‐related degeneration of elastic fibres causes skin wrinkles and loss of elasticity. A correlation has been reported between dermal elastic fibre degradation and wrinkles. However, the mechanism of wrinkle formation is complex and unclear. To establish methods for treating wrinkles, it is necessary to understand the aging‐related morphological alterations underlying elastin fibre degradation or disappearance. Objectives To image and analyse aging‐related three‐dimensional (3D) morphological alterations of elastic fibres in the eyelid and abdominal skin. Methods Excised human eyelid and abdominal skin tissues were examined. The structure of elastic fibres in the skin tissues was examined via nuclear, tropoelastin and fibrillin‐1 immunostaining. Then, 3D imaging was performed using a confocal laser microscope and tissue decolourization technology. Images were analysed using a computational method. Results The decolourization technology made it possible to image elastin fibres in 3D, and we devised a method for analyzing the elastin fibre structure using computational methods. It was quantitatively shown that the eyelid skin has a more complex fibrous structure than the abdomen, and the fibres became curved, shortened and thickened with age. Conclusions We provide a novel 3D analysis method for elastin fibres and report age‐related alterations in elastin fibre structure in the human eyelid and abdominal skin. This method contributes to the understanding of elastin fibre degeneration in more detail than conventional methods. Applying this 3D analysis method to skin tissues will contribute to a better understanding of age‐related changes in fibres and to the development of novel wrinkle treatments.
Collapse
Affiliation(s)
- T. Tohgasaki
- Fancl Research Institute Fancl Corporation Yokohama Kanagawa Japan
| | - S. Kondo
- Fancl Research Institute Fancl Corporation Yokohama Kanagawa Japan
| | - S. Nishizawa
- Fancl Research Institute Fancl Corporation Yokohama Kanagawa Japan
| | - S. Ishiwatari
- Fancl Research Institute Fancl Corporation Yokohama Kanagawa Japan
| | - T. Sakurai
- Fancl Research Institute Fancl Corporation Yokohama Kanagawa Japan
| | - S. Ishikawa
- Department of Plastic and Aesthetic Surgery Kitasato University School of Medicine Sagamihara Japan
| | - A. Takeda
- Department of Plastic and Aesthetic Surgery Kitasato University School of Medicine Sagamihara Japan
| |
Collapse
|
11
|
Sakaki Y, Urushihara M, Nagai T, Fujioka K, Kondo S, Kinoshita Y, Hattori T, Kagami S. Urinary angiotensin converting enzyme 2 and disease activity in pediatric IgA nephropathy. J Med Invest 2021; 68:292-296. [PMID: 34759147 DOI: 10.2152/jmi.68.292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Background : Our previous studies demonstrated that the intrarenal renin-angiotensin system (RAS) status was activated in pediatric patients with chronic glomerulonephritis. In the present study, we tested the hypothesis that angiotensin-converting enzyme 2 (ACE2) expression in the kidney is associated with the development of pediatric IgA nephropathy. Methods : We analyzed urinary ACE2 levels and ACE2 expression in the kidney tissues of pediatric patients with IgA nephropathy treated with RAS blockade. Paired tests were used to analyze changes from the first to the second biopsy. Results : Urinary ACE2 levels were significantly decreased after RAS blockade treatment, accompanied by decreased ACE2 expression levels in kidney tissues, urinary protein levels and mesangial hypercellularity scores. Urinary ACE2 levels at the first biopsy were positively correlated with the ACE2 expression levels. Conclusions : These data suggest that urinary ACE2 is associated with ACE2 expression in the diseased kidney, which correlates with the pathogenesis of IgA nephropathy in pediatric patients. J. Med. Invest. 68 : 292-296, August, 2021.
Collapse
Affiliation(s)
- Yuki Sakaki
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Maki Urushihara
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Takashi Nagai
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Keisuke Fujioka
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Shuji Kondo
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Yukiko Kinoshita
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Tomoki Hattori
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| | - Shoji Kagami
- Department of Pediatrics, Institute of Biomedical Scicences, The Tokushima University Graduate School, Tokushima, Japan
| |
Collapse
|
12
|
Sakai R, Sekimoto T, Arai T, Tanaka H, Ogura K, Oishi Y, Nomura K, Sakai K, Arai K, Tsujita H, Kondo S, Tsukamoto S, Mori H, Koba S, Shinke T. Contributions of small dense LDL and oxidized LDL on the formation of neoatherosclerosis in patients under statin treatment. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.3370] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Aim
In-stent neoatherosclerosis (NA) has emerged as an important contributing factor to late stent failure and cardiovascular events. The aim of this study was to investigate whether lipid markers are associated with NA using optical coherence tomography (OCT) after percutaneous coronary intervention (PCI) in patients with coronary artery disease under well-controlled low density lipoprotein cholesterol (LDL-c) on statin treatment.
Methods
We enrolled consecutive 115 patients under statin treatment who underwent PCI with current-generation drug-eluting stent for acute and chronic coronary syndrome. OCT image and various lipid markers were obtained at 1-year for scheduled research assessment. NA was defined as a lipid laden neointima or calcified neointima. Both small dense LDL-c (sd-LDL-c) and remnant lipoprotein cholesterol (RL-c) were measured using direct homogenous assay.
Results
During an average follow-up of 13 months, NA was observed in 14 (13.6%) patients. Not LDL-c but sd-LDL-c, Malondialdehyde-modified LDL (MDA-LDL) as oxidized LDL and (RL-c) were significantly higher in patients with NA. The optimal threshold values of sd-LDL-c, MDA-LDL and RL-c for predicting NA according to receiver operating characteristics analysis were 32.3 mg/dl, 91.0 U/L, and 3.3 mg/dL, respectively. On multivariate logistic regression analysis, sd-LDL-c (≥32.3 mg/dL) and MDA (≥91.0 U/L) were significantly associated with NA (odds ratio [OR]:13.62, p=0.016, OR: 12.68, p=0.01, respectively).
Conclusions
In statin-treated patients, sd-LDL-c and MDA-LDL but not LDL-c might be useful biomarkers to identify the formation of NA at 1 years after PCI. Aggressive reduction of these atherogenic LDL may have a potential to prevent the formation of NA.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- R Sakai
- Showa University Hospital, Tokyo, Japan
| | | | - T Arai
- Showa University Hospital, Tokyo, Japan
| | - H Tanaka
- Showa University Hospital, Tokyo, Japan
| | - K Ogura
- Showa University Hospital, Tokyo, Japan
| | - Y Oishi
- Showa University Hospital, Tokyo, Japan
| | - K Nomura
- Showa University Hospital, Tokyo, Japan
| | - K Sakai
- Showa University Hospital, Tokyo, Japan
| | - K Arai
- Showa University Hospital, Tokyo, Japan
| | - H Tsujita
- Showa University Hospital, Tokyo, Japan
| | - S Kondo
- Showa University Hospital, Tokyo, Japan
| | | | - H Mori
- Showa University Hospital, Tokyo, Japan
| | - S Koba
- Showa University Hospital, Tokyo, Japan
| | - T Shinke
- Showa University Hospital, Tokyo, Japan
| |
Collapse
|
13
|
Arai T, Sekimoto T, Mori H, Sakai R, Tanaka H, Oishi Y, Ogura K, Nomura K, Sakai K, Tsujita H, Kondo S, Koba S, Shinke T. Higher plasma level of small dense low-density lipoprotein cholesterol in ST-segment-elevation myocardial infarction patients with plaque rupture. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.2569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Aim
The aim of this study was to compare small dense low-density lipoprotein cholesterol (sd-LDL-c) and various lipid markers between patients exhibiting plaque rupture (PR) in the culprit lesions evaluated by optical coherence tomography (OCT) imaging and those without PR in ST-segment elevation myocardial infarction (STEMI) patients.
Methods
We studied consecutive 60 de novo culprit lesions in 60 patients with STEMI who underwent pre-intervention OCT. PR was defined as a plaque containing a cavity that had overlying residual fibrous caps. Plasma sd-LDL-c was measured directly by homogeneous assay at the time of primary percutaneous coronary intervention.
Results
The patients were classified into PR (n=40, 66.7%) or non-PR (n=20, 33.3%). There were no significant differences in low-density lipoprotein cholesterol (LDL-c), non-high-density lipoprotein cholesterol (non-HDL-c) and pre-admission statin therapy between two groups (135.1±38.0 mg/dL vs 129.2±43.8 mg/dL; p=0.35, 157.1±37.4 mg/dL vs 143.0±37.7 mg/dL; p=0.24, 15.0% vs 20.0%; p=0.93). However, sd-LDL-c level was significantly higher in patients with PR than those with non-PR (44.0±18.1 mg/dL vs 28.0±9.3 mg/dL; p=0.0005). On multiple logistic regression analysis, sd-LDL-c was an independent predictor of PR (odds ratio, 1.14 per 1 mg/dL; p=0.0063).
Conclusion
Sd-LDL-c was significantly associated with PR of the culprit lesion in patients with STEMI.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- T Arai
- Showa University Hospital, Tokyo, Japan
| | | | - H Mori
- Showa University Hospital, Tokyo, Japan
| | - R Sakai
- Showa University Hospital, Tokyo, Japan
| | - H Tanaka
- Showa University Hospital, Tokyo, Japan
| | - Y Oishi
- Showa University Hospital, Tokyo, Japan
| | - K Ogura
- Showa University Hospital, Tokyo, Japan
| | - K Nomura
- Showa University Hospital, Tokyo, Japan
| | - K Sakai
- Showa University Hospital, Tokyo, Japan
| | - H Tsujita
- Showa University Hospital, Tokyo, Japan
| | - S Kondo
- Showa University Hospital, Tokyo, Japan
| | - S Koba
- Showa University Hospital, Tokyo, Japan
| | - T Shinke
- Showa University Hospital, Tokyo, Japan
| |
Collapse
|
14
|
Ishimaru N, Fujikawa H, Kondo S, Kobayashi Y. Ectopic ovary presenting as mesenteric abscess. Ann R Coll Surg Engl 2021; 103:e285-e287. [PMID: 34414779 DOI: 10.1308/rcsann.2021.0032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Ectopic ovary is a rare gynaecological condition that results in problems with menstruation and pregnancy and may develop into a malignant tumour. However, as the condition is often asymptomatic, diagnosis is difficult and frequently delayed. We report a case of a 42-year-old female who presented with a 10-day history of abdominal pain. The patient underwent surgery that confirmed the diagnosis of an ectopic ovary with an internal abscess. The findings of our study indicate that ectopic ovaries can present with an abscess. Ectopic ovaries should be included in the differential diagnosis of masses with internal abscesses.
Collapse
Affiliation(s)
| | - H Fujikawa
- Suwa Central Hospital, Nagano, Japan.,The University of Tokyo, Tokyo, Japan
| | - S Kondo
- Suwa Central Hospital, Nagano, Japan
| | | |
Collapse
|
15
|
Hibino Y, Ito M, Satake T, Kondo S. Clinical benefits of precision medicine in treating solid cancers: European Society of Medical Oncology-Magnitude of Clinical Benefit Scale score-based analysis. ESMO Open 2021; 6:100187. [PMID: 34118770 PMCID: PMC8207218 DOI: 10.1016/j.esmoop.2021.100187] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2021] [Revised: 05/16/2021] [Accepted: 05/23/2021] [Indexed: 11/15/2022] Open
Abstract
Background Precision and matched cancer medicine has the potential to complement the existing biomarker approaches in cancer treatment. However, despite their promising potential, certain negative results have highlighted their limitations in molecular biology-driven treatment strategies. This study aimed to evaluate the clinical benefits of precision therapies. Materials and methods Three reviewers independently identified and assessed precision and matched cancer treatment studies published between January 2015 and December 2020. Clinical benefits of the treatments included in our cohort were assessed using two established frameworks; the European Society of Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS) and the American Society of Clinical Oncology Value Framework. Results Of the 290 eligible studies, 130 were for lung cancer, 51 for solid tumors, 24 for melanoma, and 24 for breast cancer. The common targets were: epidermal growth factor receptor (N = 66), serine/threonine-protein kinase B-Raf (N = 40), anaplastic lymphoma kinase (ALK) (N = 34), breast cancer protein (N = 26), phosphatidylinositol-3 kinase/protein kinase B/phosphatase and tensin homolog (PI3K/AKT/PTEN) pathway (N = 19), receptor tyrosine-protein kinase erbB-2 (HER2) (N = 19), mitogen-activated protein kinase (RAS/RAF/MAPK) pathway (N = 18), programmed death-ligand 1 (N = 12), fibroblast growth factor receptor (N = 8), and others (N = 43). The ESMO-MCBS scales ranged from 0 to 4. Based on the clinical benefit values, tumor mutational burden/mismatch repair-deficient/microsatellite instability-high for immunotherapy, anaplastic lymphoma kinase, and neurotrophic receptor tyrosine kinase therapeutic targets were considered high, whereas RAS/RAF/MAPK and PI3K/AKT/PTEN were considered low. Additionally, we found a significant difference between each average score (P < 0.001). Conclusions This study showed that precision and matched cancer therapies require further improvement. This is consistent with the views of the tumor board and of clinicians that precision strategies need to be revised to improve their therapeutic effects. Of the 290 eligible studies, 130 were for lung cancer, 51 for solid tumors, 24 for melanoma, and 24 for breast cancer. Precision strategies need to be revised to improve their therapeutic effects. Therapeutic targets need to be narrowed down to improve the efficacy of precision medicine in the clinical setting.
Collapse
Affiliation(s)
- Y Hibino
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
| | - M Ito
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan
| | - T Satake
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - S Kondo
- Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan; Outpatient Treatment Center, National Cancer Center Hospital, Tokyo, Japan.
| |
Collapse
|
16
|
Fujioka K, Takeuchi S, Tayama T, Takei M, Ono A, Shono M, Shichijo K, Narita T, Kondo S. Escherichia coli pyomyositis in a patient with Down syndrome: A case report. IDCases 2021; 24:e01158. [PMID: 34026545 PMCID: PMC8134725 DOI: 10.1016/j.idcr.2021.e01158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Revised: 05/05/2021] [Accepted: 05/06/2021] [Indexed: 12/05/2022] Open
Abstract
Pyomyositis is an infection of the skeletal muscle that involves intramuscular abscess formation. It is typically caused by gram-positive bacteria, especially Staphylococcus aureus. Few cases of Escherichia coli pyomyositis have been reported in immunocompromised adult patients, while none have been reported in children. We present a case of a 4-year-old boy with Down syndrome who developed Escherichia coli pyomyositis. The patient presented to our hospital with a fever and right forearm swelling. The magnetic resonance imaging findings suggested pyomyositis of the right forearm muscle and osteomyelitis of the distal radius. Both the blood and puncture fluid cultures were negative. Cefazolin and vancomycin were administered, and his blood examination results and right forearm swelling improved; however, a slight fever persisted. The multiplex polymerase chain reaction isolated the chuA gene but not the YjaA gene; thus the patient was diagnosed with pyomyositis and osteomyelitis caused by Escherichia coli group D. The cefazolin was substituted with meropenem, and the vancomycin was discontinued. Thereafter, his fever promptly improved, which indicated that the cause of persistent fever was vancomycin drug fever. The patient was discharged after receiving 3 weeks of intravenous antimicrobial therapy, and recovered fully with no long-term sequelae. To the best of our knowledge, this is the first reported case of Escherichia coli pyomyositis in a child. The findings in this case suggest that Escherichia coli should be considered when choosing initial empiric therapy for pyomyositis, especially in children with underlying conditions.
Collapse
Affiliation(s)
- Keisuke Fujioka
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Shunsuke Takeuchi
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Takahiro Tayama
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Mikiko Takei
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Akemi Ono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Miki Shono
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Koichi Shichijo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| | - Tsutomu Narita
- Narita Child Clinic, Tenno-cho 32-9, Takatsuki, Osaka 569-0088, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima Prefectural Central Hospital, Kuramoto-cho 1-10-3, Tokushima, Tokushima 770-8539, Japan
| |
Collapse
|
17
|
Kusunoki K, Toiyama Y, Okugawa Y, Yamamoto A, Omura Y, Kusunoki Y, Yin C, Kondo S, Okita Y, Ohi M, Sasaki H, Bando T, Uchino M, Ikeuchi H, Kusunoki M. The advanced lung cancer inflammation index predicts outcomes in patients with Crohn's disease after surgical resection. Colorectal Dis 2021; 23:84-93. [PMID: 32644245 DOI: 10.1111/codi.15248] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/05/2020] [Accepted: 06/25/2020] [Indexed: 12/13/2022]
Abstract
AIM Precise biomarkers for predicting prognosis could help to identify high-risk Crohn's disease (CD) patients to facilitate better follow-up during the postoperative course. In this study, the primary aim is the identification of the most reliable nutrition marker that predicts surgical relapse in CD patients. METHOD We first evaluated the predictive value of various nutrition markers for postoperative surgical relapse in CD patients and identified the advanced lung cancer inflammation index (ALI) as a promising biomarker. Then, we assessed the clinical significance of preoperative ALI in CD patients using two cohorts. RESULTS Preoperative ALI showed the highest correlation with reoperation rate compared with other nutritional parameters in CD patients receiving surgical resection (sensitivity 53%, specificity 86%, area under the curve 0.71). Lower levels of preoperative ALI were significantly correlated with the presence of perianal disease. A lower level of preoperative ALI was an independent prognostic factor for reoperation rate after an intestinal resection (hazard ratio 3.37, 95% CI 1.38-10.12, P = 0.006), and the prognostic impact of preoperative ALI was successfully validated in an independent cohort using the same cut-off value. CONCLUSION Preoperative ALI might be useful for postoperative management of CD patients.
Collapse
Affiliation(s)
- K Kusunoki
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan.,Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - Y Toiyama
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - Y Okugawa
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan.,Department of Genomic Medicine, Mie University Hospital, Tsu, Japan
| | - A Yamamoto
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - Y Omura
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - Y Kusunoki
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - C Yin
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - S Kondo
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - Y Okita
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - M Ohi
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| | - H Sasaki
- Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - T Bando
- Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - M Uchino
- Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - H Ikeuchi
- Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
| | - M Kusunoki
- Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan
| |
Collapse
|
18
|
Tanaka A, Watanabe K, Kondo S, Tamura N, Nishimoto T, Yoshida Y. Purification of human iPSC-derived cardiomyocytes by HDAC inhibition through inducing apoptosis and cell arrest in non-cardiomyocytes. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.3655] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Cell therapy is one of the most promising strategies for treatment of heart failure. During preparation of iPSC-derived cardiomyocytes for cells therapy, it is important to eliminate the presence of residual proliferative non-target cells in the preparation as these non-target cells could present the risk of tumorgenicity. To minimize the risk, selective and more precise purification process is necessary.
Purpose
We hypothesized that the differences in proliferative activity between cardiomyocytes and non-target cells might result in different sensitivities to the drugs targeting cell growth/survival. The aim of this study is to obtain compounds that eliminate non-cardiomyocytes selectively and to study the mechanism of action of these compounds.
Methods and results
We screened 314 small compounds using both iPSCs and sorted hiPSC-derived cardiomyocytes (hiPSC-CMs). We identified several compounds, which markedly decreased the cell numbers of iPSCs, but showed minimum effects on those of hiPSC-CMs. Among them, HDAC inhibitors were selected as the most promising candidates. We examined whether HDAC inhibitors could purify hiPSC-CMs containing non-cardiomyocytes populations, which were differentiated using the classical embryoid body (EB) method. As a result, HDAC inhibitors increased the purity of cardiomyocytes (up to 98%) by decreasing non-target cells such as smooth muscle cells, endothelial cells, and endodermal lineage cells. Moreover, we confirmed HDAC inhibitors could be used for purification of cardiomyocytes in monolayer differentiation protocol using GSK3β inhibitor and Wnt inhibitor. We measured the expression levels of mRNA and protein in iPSCs and hiPSC-CMs (EB method) treated with HDAC inhibitors. mRNA levels of CDKN1A (p21) and BAX were upregulated in iPSCs. Western blotting analyses revealed that HDAC inhibitors also induced the expression of p21 and the cleavage of Caspase3 in iPSCs.
Conclusions
Our result suggests that the inhibition of HDAC enables an efficient purification of hiPSC-CMs in multiple differentiation methods. Furthermore, our data indicate that HDAC inhibitors induce the apoptosis and cell cycle arrest in iPSCs but not hiPSC-CMs.
Figure 1
Funding Acknowledgement
Type of funding source: Private company. Main funding source(s): Takeda Pharmaceutical Company Limited
Collapse
Affiliation(s)
- A Tanaka
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - K Watanabe
- Takeda Pharmaceutical Company Limited, Pharmaceutical Sciences, Fujisawa, Japan
| | - S Kondo
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - N Tamura
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - T Nishimoto
- Takeda Pharmaceutical Company Limited, T-CiRA Discovery, Fujisawa, Japan
| | - Y Yoshida
- Center for iPS Cell Research and Application, Kyoto University, Kyoto, Japan
| |
Collapse
|
19
|
Ogura K, Tsujita H, Arai T, Sakai R, Tanaka H, Masaki R, Oishi Y, Nomura K, Arai K, Sekimoto T, Kondo S, Tsukamoto S, Mori H, Matsumoto H, Shinke T. Early vascular healing following bioresorbable-polymer sirolimus-eluting stent implantation in comparison with durable-polymer everolimus-eluting stent: sequential optical coherence tomography study. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1391] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Orsiro ultrathin-strut bioresorbable-polymer sirolimus-eluting stent (BP-SES) might facilitate early vascular healing responses that seems to be associated with improved long-term clinical outcomes. We compared the early vascular healing responses to BP-SES and Xience durable-polymer everolimus-eluting stent (DP-EES) in patients with chronic coronary syndrome (CCS) using optical coherence tomography (OCT).
Methods
A total of 40 patients with CCS receiving OCT-guided PCI were included. 20 patients were assigned to BP-SES, and 20 to DP-EES. OCT was performed immediately after stent placement (post-procedure) and at 1 month follow-up. Struts were recorded as uncovered if any part was visibly exposed in the lumen or covered if a layer of tissue covered all reflecting surfaces. The incidence of intrastent thrombus (IS-Th) and irregular protrusion (IRP) were also assessed.
Results
At 1 month, the percentage of uncovered struts was significantly lower in the BP-SES compared with the DP-EES (2.8±1.6% vs. 5.8±1.8%, respectively; p<0.001), and that of malapposed struts was similar between both groups (2.5±3.1% vs. 2.4±2.2%; p=0.76). There were no differences in the incidence of IS-Th (65.0% vs. 55.0% at post-procedure; p=0.54, 30.0% vs. 35.0% at 1 month; p=0.75) and IRP (30.0% vs. 25.0% at post-procedure; p=0.74). IRP had completely resolved at 1 month in both groups.
Conclusion
Early vascular healing response to Orsiro BP-SES implantation was revealed in CCS patients at 1 month compared with Xience DP-EES. Orsiro BP-SES may have a potential to shorten the dual antiplatelet therapy duration.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- K Ogura
- Showa University Hospital, Tokyo, Japan
| | - H Tsujita
- Showa University Hospital, Tokyo, Japan
| | - T Arai
- Showa University Hospital, Tokyo, Japan
| | - R Sakai
- Showa University Hospital, Tokyo, Japan
| | - H Tanaka
- Showa University Hospital, Tokyo, Japan
| | - R Masaki
- Showa University Hospital, Tokyo, Japan
| | - Y Oishi
- Showa University Hospital, Tokyo, Japan
| | - K Nomura
- Showa University Hospital, Tokyo, Japan
| | - K Arai
- Showa University Hospital, Tokyo, Japan
| | | | - S Kondo
- Showa University Hospital, Tokyo, Japan
| | | | - H Mori
- Showa University Hospital, Tokyo, Japan
| | | | - T Shinke
- Showa University Hospital, Tokyo, Japan
| |
Collapse
|
20
|
Oishi Y, Shinke T, Tanaka H, Ogura K, Arai K, Masaki R, Nomura K, Kosaki R, Sakai K, Sekimoto T, Tsujita H, Kondo S, Tsukamoto S, Mori H, Matsumoto H. Early vascular responses to ultrathin biodegradable polymer sirolimus-eluting stent for the treatment of st-elevation myocardial infarction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Recent clinical study suggests newer-generation drug-eluting stents (DES) that combine ultrathin strut and nano-coating with biodegradable polymers sirolimus-eluting stent (BP-SES) could improve long-term clinical outcomes in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI) over current generation DES. However, safety profiles in very early phase have not been systematically addressed.
Objective and method
We exploratory investigate early vascular response following BP-SES implantation in patients with STEMI to reveal mechanism of the favorable clinical outcomes in recent studies using frequency domain-optical coherence tomography (FD-OCT).
Consecutive twenty patients with STEMI who underwent FD-OCT immediately after primary PCI and were eligible for follow-up FD-OCT at 2 weeks after implantation were enrolled between June 2018 and November 2019.
Results
Twenty patients (age 62.7±11.3 years, male 85.0%) were enrolled with frequencies of hypertension (45.0%), diabetes mellitus (35.0%), dyslipidemia (55.0%) and smoking (80.0%). Aspiration catheter were used in all patients, and 1.13±0.34 stents were used. Only one patient (5.0%) received chronic antiplatelet therapy with aspirin prior to the onset of STEMI. All patients started to receive prasugrel as thienopyridine from this event and continued dual antiplatelet therapy for 2 weeks.
The percentage of uncovered struts significantly decreased from post-procedure to 2W follow-up (69±18% post-procedure versus 30±11% at 2W follow up, p<0.0001). Malapposed struts also decreased (5.6±5.7% post-procedure versus0.9±1.2% at 2W follow up, p<0.0001).The average protrusion area of athero-thrombotic burden numerically decreased (0.37±0.19 at post-procedure versus 0.34±0.14 mm2 at 2W follow up, p=0.19) and its volume showed similar tendency (10.60±6.40 at post-procedure versus 9.36±5.14 mm3 at 2W follow up, p=0.19).
Conclusion(s)
This study firstly elucidated very early vascular responses following ultrathin strut BP-SES implantation in STEMI patients, showing early progression of strut coverage and resolution of athero-thrombotic materials. This technology may have a potential to overcome the current generation DESs in this clinical setting.
Thrombus, uncovered and malapposed struts
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- Y Oishi
- Showa University Hospital, Tokyo, Japan
| | - T Shinke
- Showa University Hospital, Tokyo, Japan
| | - H Tanaka
- Showa University Hospital, Tokyo, Japan
| | - K Ogura
- Showa University Hospital, Tokyo, Japan
| | - K Arai
- Showa University Hospital, Tokyo, Japan
| | - R Masaki
- Showa University Hospital, Tokyo, Japan
| | - K Nomura
- Showa University Hospital, Tokyo, Japan
| | - R Kosaki
- Showa University Hospital, Tokyo, Japan
| | - K Sakai
- Showa University Hospital, Tokyo, Japan
| | | | - H Tsujita
- Showa University Hospital, Tokyo, Japan
| | - S Kondo
- Showa University Hospital, Tokyo, Japan
| | | | - H Mori
- Showa University Hospital, Tokyo, Japan
| | | |
Collapse
|
21
|
Niitsuma S, Kudo H, Kikuchi A, Hayashi T, Kumakura S, Kobayashi S, Okuyama Y, Kumagai N, Niihori T, Aoki Y, So T, Funayama R, Nakayama K, Shirota M, Kondo S, Kagami S, Tsukaguchi H, Iijima K, Kure S, Ishii N. Biallelic variants/mutations of IL1RAP in patients with steroid-sensitive nephrotic syndrome. Int Immunol 2020; 32:283-292. [PMID: 31954058 DOI: 10.1093/intimm/dxz081] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2019] [Accepted: 12/19/2019] [Indexed: 12/11/2022] Open
Abstract
Nephrotic syndrome (NS) is a renal disease characterized by severe proteinuria and hypoproteinemia. Although several single-gene mutations have been associated with steroid-resistant NS, causative genes for steroid-sensitive NS (SSNS) have not been clarified. While seeking to identify causative genes associated with SSNS by whole-exome sequencing, we found compound heterozygous variants/mutations (c.524T>C; p.I175T and c.662G>A; p.R221H) of the interleukin-1 receptor accessory protein (IL1RAP) gene in two siblings with SSNS. The siblings' parents are healthy, and each parent carries a different heterozygous IL1RAP variant/mutation. Since IL1RAP is a critical subunit of the functional interleukin-1 receptor (IL-1R), we investigated the effect of these variants on IL-1R subunit function. When stimulated with IL-1β, peripheral blood mononuclear cells from the siblings with SSNS produced markedly lower levels of cytokines compared with cells from healthy family members. Moreover, IL-1R with a variant IL1RAP subunit, reconstituted on a hematopoietic cell line, had impaired binding ability and low reactivity to IL-1β. Thus, the amino acid substitutions in IL1RAP found in these NS patients are dysfunctional variants/mutations. Furthermore, in the kidney of Il1rap-/- mice, the number of myeloid-derived suppressor cells, which require IL-1β for their differentiation, was markedly reduced although these mice did not show significantly increased proteinuria in acute nephrotic injury with lipopolysaccharide treatment. Together, these results identify two IL1RAP variants/mutations in humans for the first time and suggest that IL1RAP might be a causative gene for familial NS.
Collapse
Affiliation(s)
- Sou Niitsuma
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan.,Department of Pediatrics, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Hiroki Kudo
- Department of Pediatrics, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Atsuo Kikuchi
- Department of Pediatrics, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Takaya Hayashi
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Satoshi Kumakura
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan.,Department of Nephrology, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Shuhei Kobayashi
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Yuko Okuyama
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Naonori Kumagai
- Department of Pediatrics, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Tetsuya Niihori
- Department of Medical Genetics, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Yoko Aoki
- Department of Medical Genetics, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Takanori So
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan.,Laboratory of Molecular Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan
| | - Ryo Funayama
- Division of Cell Proliferation, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Keiko Nakayama
- Division of Cell Proliferation, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Matsuyuki Shirota
- Division of Interdisciplinary Medical Science, United Centers for Advanced Research and Translational Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan
| | - Shuji Kondo
- Department of Pediatrics, Tokushima University Graduate School, Tokushima, Japan.,Department of Pediatrics, NHO Shikoku Medical Center for Children and Adults, Zentsuji, Japan
| | - Shoji Kagami
- Department of Pediatrics, Tokushima University Graduate School, Tokushima, Japan
| | - Hiroyasu Tsukaguchi
- Second Department of Internal Medicine, Kansai Medical University, Hirakata, Japan
| | - Kazumoto Iijima
- Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe, Japan
| | - Shigeo Kure
- Department of Pediatrics, Endocrinology and Vascular Medicine, Sendai, Japan
| | - Naoto Ishii
- Department of Microbiology and Immunology, Endocrinology and Vascular Medicine, Sendai, Japan
| |
Collapse
|
22
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. 73P Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.051] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
23
|
Urushihara M, Kondo S, Kinoshita Y, Ozaki N, Jamba A, Nagai T, Fujioka K, Hattori T, Kagami S. (Pro)renin receptor promotes crescent formation via the ERK1/2 and Wnt/β-catenin pathways in glomerulonephritis. Am J Physiol Renal Physiol 2020; 319:F571-F578. [PMID: 32830537 DOI: 10.1152/ajprenal.00250.2020] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
(Pro)renin receptor [(P)RR] has multiple functions, but its regulation and role in the pathogenesis in glomerulonephritis (GN) are poorly defined. The aims of the present study were to determine the effects of direct renin inhibition (DRI) and demonstrate the role of (P)RR on the progression of crescentic GN. The anti-glomerular basement membrane nephritis rat model developed progressive proteinuria (83.64 ± 10.49 mg/day) and glomerular crescent formation (percent glomerular crescent: 62.1 ± 2.3%) accompanied by increased macrophage infiltration and glomerular expression of monocyte chemoattractant protein (MCP)-1, (P)RR, phospho-extracellular signal-regulated kinase (ERK)1/2, Wnt4, and active β-catenin. Treatment with DRI ameliorated proteinuria (20.33 ± 5.88 mg/day) and markedly reduced glomerular crescent formation (20.9 ± 2.6%), induction of macrophage infiltration, (P)RR, phospho-ERK1/2, Wnt4, and active β-catenin. Furthermore, primary cultured parietal epithelial cells stimulated by recombinant prorenin showed significant increases in cell proliferation. Notably, while the ERK1/2 inhibitor PD98059 or (P)RR-specific siRNA treatment abolished the elevation in cell proliferation, DRI treatment did not abrogate this elevation. Moreover, cultured mesangial cells showed an increase in prorenin-induced MCP-1 expression. Interestingly, (P)RR or Wnt4-specific siRNA treatment or the β-catenin antagonist XAV939 inhibited the elevation of MCP-1 expression, whereas DRI did not. These results suggest that (P)RR regulates glomerular crescent formation via the ERK1/2 signaling and Wnt/β-catenin pathways during the course of anti-glomerular basement membrane nephritis and that DRI mitigates the progression of crescentic GN through the reduction of (P)RR expression but not inhibition of prorenin binding to (P)RR.
Collapse
Affiliation(s)
- Maki Urushihara
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Shuji Kondo
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Yukiko Kinoshita
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Natsuko Ozaki
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Ariunbold Jamba
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Takashi Nagai
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Keisuke Fujioka
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Tomoki Hattori
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| | - Shoji Kagami
- Department of Pediatrics, Institute of Health Biosciences, The Tokushima University Graduate School, Tokushima, Japan
| |
Collapse
|
24
|
Tohgasaki T, Kondo S, Nishizawa S, Yu X, Ishiwatari S, Sakurai T. 862 Thioredoxin regenerates elastic fibers in the dermis. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
25
|
Rosenbaum S, Morell R, Abdel-Baki A, Ahmadpanah M, Anilkumar TV, Baie L, Bauman A, Bender S, Boyan Han J, Brand S, Bratland-Sanda S, Bueno-Antequera J, Camaz Deslandes A, Carneiro L, Carraro A, Castañeda CP, Castro Monteiro F, Chapman J, Chau JY, Chen LJ, Chvatalova B, Chwastiak L, Corretti G, Dillon M, Douglas C, Egger ST, Gaughran F, Gerber M, Gobbi E, Gould K, Hatzinger M, Holsboer-Trachsler E, Hoodbhoy Z, Imboden C, Indu PS, Iqbal R, Jesus-Moraleida FR, Kondo S, Ku PW, Lederman O, Lee EHM, Malchow B, Matthews E, Mazur P, Meneghelli A, Mian A, Morseth B, Munguia-Izquierdo D, Nyboe L, O’Donoghue B, Perram A, Richards J, Romain AJ, Romaniuk M, Sadeghi Bahmani D, Sarno M, Schuch F, Schweinfurth N, Stubbs B, Uwakwe R, Van Damme T, Van Der Stouwe E, Vancampfort D, Vetter S, Waterreus A, Ward PB. Assessing physical activity in people with mental illness: 23-country reliability and validity of the simple physical activity questionnaire (SIMPAQ). BMC Psychiatry 2020; 20:108. [PMID: 32143714 PMCID: PMC7060599 DOI: 10.1186/s12888-020-2473-0] [Citation(s) in RCA: 57] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/15/2019] [Accepted: 01/30/2020] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Physical inactivity is a key contributor to the global burden of disease and disproportionately impacts the wellbeing of people experiencing mental illness. Increases in physical activity are associated with improvements in symptoms of mental illness and reduction in cardiometabolic risk. Reliable and valid clinical tools that assess physical activity would improve evaluation of intervention studies that aim to increase physical activity and reduce sedentary behaviour in people living with mental illness. METHODS The five-item Simple Physical Activity Questionnaire (SIMPAQ) was developed by a multidisciplinary, international working group as a clinical tool to assess physical activity and sedentary behaviour in people living with mental illness. Patients with a DSM or ICD mental illness diagnoses were recruited and completed the SIMPAQ on two occasions, one week apart. Participants wore an Actigraph accelerometer and completed brief cognitive and clinical assessments. RESULTS Evidence of SIMPAQ validity was assessed against accelerometer-derived measures of physical activity. Data were obtained from 1010 participants. The SIMPAQ had good test-retest reliability. Correlations for moderate-vigorous physical activity was comparable to studies conducted in general population samples. Evidence of validity for the sedentary behaviour item was poor. An alternative method to calculate sedentary behaviour had stronger evidence of validity. This alternative method is recommended for use in future studies employing the SIMPAQ. CONCLUSIONS The SIMPAQ is a brief measure of physical activity and sedentary behaviour that can be reliably and validly administered by health professionals.
Collapse
Affiliation(s)
- S. Rosenbaum
- grid.1005.40000 0004 4902 0432School of Psychiatry, UNSW Sydney, Sydney, Australia
| | - R. Morell
- grid.1005.40000 0004 4902 0432School of Psychiatry, UNSW Sydney, Sydney, Australia
| | - A. Abdel-Baki
- grid.410559.c0000 0001 0743 2111Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Canada
| | - M. Ahmadpanah
- grid.411950.80000 0004 0611 9280Behavioral Disorders and Substances Abuse Research Center, Hamadan University of Medical Sciences, Hamadan, Iran
| | - T. V. Anilkumar
- grid.413226.00000 0004 1799 9930Department of Psychiatry, Government Medical College, Trivandrum, India
| | - L. Baie
- grid.16149.3b0000 0004 0551 4246Department of Psychosomatics and Psychotherapy, University Hospital Münster, Münster, Germany
| | - A. Bauman
- grid.1013.30000 0004 1936 834XSchool of Public Health, University of Sydney, Sydney, Australia
| | - S. Bender
- LWL-Klinik Marsberg, Hospital for Psychiatry, Psychotherapy and Psychosomatics, Marsberg, Germany
| | - J. Boyan Han
- grid.253561.60000 0001 0806 2909California State University, Los Angeles, USA
| | - S. Brand
- grid.6612.30000 0004 1937 0642University of Basel, Psychiatric Clinics, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland ,grid.12711.340000 0001 2369 7670Department of Biomolecular Sciences, University of Urbino, Urbino, Italy ,grid.477714.60000 0004 0587 919XThe Sutherland Hospital, South Eastern Sydney Local Health District, Sydney, Australia
| | - S. Bratland-Sanda
- Department of Sport, Physical Education and Outdoor Studies, University of South-Eastern Norway, Bø, Notodden, Norway
| | - J. Bueno-Antequera
- grid.15449.3d0000 0001 2200 2355Physical Performance & Sports Research Center, Department of Sports and Computer Science, Section of Physical Education and Sports, Faculty of Sports Sciences, Universidad Pablo de Olavide, Seville, Spain
| | - A. Camaz Deslandes
- grid.8536.80000 0001 2294 473XPsychiatry Institute, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - L. Carneiro
- Research Centre in Sports Sciences, Health Sciences and Human Development, CIDESD, GERON Research Community, Vila Real, Portugal
| | - A. Carraro
- grid.34988.3e0000 0001 1482 2038Faculty of Education, Free University of Bolzano, Bolzano, Italy
| | - C. P. Castañeda
- Early Intervention Program, JHorwitz Psychiatric Institute, Santiago, Chile
| | - F. Castro Monteiro
- grid.8532.c0000 0001 2200 7498Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - J. Chapman
- grid.1049.c0000 0001 2294 1395QIMR Berghofer Medical Research Institute, Brisbane, Australia
| | - J. Y. Chau
- grid.1013.30000 0004 1936 834XSchool of Public Health, University of Sydney, Sydney, Australia ,grid.1004.50000 0001 2158 5405Department of Health Systems and Populations, Macquarie University, Sydney, Australia
| | - L. J. Chen
- grid.445057.7Department of Exercise Health Science, National Taiwan University of Sport, Taichung, Taiwan
| | - B. Chvatalova
- grid.447902.cNational Institute of Mental Health, Klecany, Czech Republic
| | - L. Chwastiak
- grid.34477.330000000122986657Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, USA
| | - G. Corretti
- Department of Mental Health, North-West Tuscany, Italy
| | - M. Dillon
- HSE Louth Meath Mental Health Services, Louth, Ireland
| | - C. Douglas
- South Coast Private Hospital, Wollongong, Australia
| | - S. T. Egger
- grid.10863.3c0000 0001 2164 6351Department of Psychiatry, Faculty of Medicine, University of Oviedo, Oviedo, Spain ,grid.7400.30000 0004 1937 0650Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland
| | - F. Gaughran
- grid.451052.70000 0004 0581 2008South London and Maudesley NHS Foundation Trust, London, UK
| | - M. Gerber
- grid.12711.340000 0001 2369 7670Department of Biomolecular Sciences, University of Urbino, Urbino, Italy
| | - E. Gobbi
- grid.6612.30000 0004 1937 0642Department of Sport, Exercise and Health, Division of Sport and Psychosocial Health, University of Basel, Basel, Switzerland
| | - K. Gould
- grid.460013.0St John of God Hospital, North Richmond, Australia
| | - M. Hatzinger
- Psychiatric Services Solothurn, Solothurn, Switzerland
| | - E. Holsboer-Trachsler
- grid.6612.30000 0004 1937 0642Adult Psychiatric Clinics (UPKE), University of Basel, Basel, Switzerland
| | - Z. Hoodbhoy
- grid.7147.50000 0001 0633 6224Department of Paediatrics and Child Health, The Aga Khan University, Karachi, Pakistan
| | - C. Imboden
- Psychiatric Services Solothurn, Solothurn, Switzerland ,Private Clinic Wyss, Muenchenbuchsee, Switzerland
| | - P. S. Indu
- grid.413226.00000 0004 1799 9930Department of Community Medicine, Government Medical College, Trivandrum, India
| | - R. Iqbal
- grid.7147.50000 0001 0633 6224Department of Community Health Sciences, Aga Khan University, Karachi, Pakistan
| | - F. R. Jesus-Moraleida
- grid.8395.70000 0001 2160 0329Department of Physical Therapy, Universidade Federal do Ceará, Fortaleza, Brazil
| | - S. Kondo
- grid.412708.80000 0004 1764 7572Department of Neuropsychiatry, The University of Tokyo Hospital, Tokyo, Japan
| | - P. W. Ku
- grid.412038.c0000 0000 9193 1222Graduate Institute of Sports and Health, National Changhua University of Education, Changhua, Taiwan
| | - O. Lederman
- grid.477714.60000 0004 0587 919XKeeping the Body In Mind, South Eastern Sydney Local Health District, Sydney, Australia
| | - E. H. M. Lee
- grid.194645.b0000000121742757Department of Psychiatry, University of Hong Kong, Hong Kong, China
| | - B. Malchow
- grid.411984.10000 0001 0482 5331Department of Psychiatry and Psychotherapy, University Medical Center Göttingen, Göttingen, Germany
| | - E. Matthews
- grid.24349.380000000106807997School of Health Sciences, Waterford Institute of Technology, Waterford, Ireland
| | - P. Mazur
- LWL-Klinik Marsberg, Hospital for Psychiatry, Psychotherapy and Psychosomatics, Marsberg, Germany
| | - A. Meneghelli
- Association of early intervention in mental disorders-Cambiare la Rotta-Onlus, Milano, Italy
| | - A. Mian
- grid.7147.50000 0001 0633 6224Department of Psychiatry, Aga Khan University, Karachi, Pakistan
| | - B. Morseth
- grid.10919.300000000122595234School of Sport Sciences, UiT The Arctic University of Norway, Tromsø, Norway
| | - D. Munguia-Izquierdo
- grid.15449.3d0000 0001 2200 2355Physical Performance & Sports Research Center, Department of Sports and Computer Science, Section of Physical Education and Sports, Faculty of Sports Sciences, Universidad Pablo de Olavide, Seville, Spain
| | - L. Nyboe
- grid.154185.c0000 0004 0512 597XDepartment of Affective Disorders, Aarhus University Hospital, Aarhus, Denmark
| | - B. O’Donoghue
- grid.488501.0Orygen, the National Centre of Excellence in Youth Mental Health, Melbourne, Australia
| | - A. Perram
- grid.267827.e0000 0001 2292 3111Faculty of Health, Victoria University Wellington, Wellington, New Zealand
| | - J. Richards
- grid.1013.30000 0004 1936 834XSchool of Public Health, University of Sydney, Sydney, Australia ,Gallipoli Medical Research Institute, Brisbane, Australia
| | - A. J. Romain
- grid.410559.c0000 0001 0743 2111Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montreal, Canada
| | - M. Romaniuk
- grid.412112.50000 0001 2012 5829Kermanshah University of Medical Sciences, Sleep Disorders and Substance Abuse Prevention Research Center, Kermanshah, Iran
| | - D. Sadeghi Bahmani
- grid.6612.30000 0004 1937 0642University of Basel, Psychiatric Clinics, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland ,grid.477714.60000 0004 0587 919XThe Sutherland Hospital, South Eastern Sydney Local Health District, Sydney, Australia
| | - M. Sarno
- Association of early intervention in mental disorders-Cambiare la Rotta-Onlus, Milano, Italy
| | - F. Schuch
- grid.411239.c0000 0001 2284 6531Department of Sports Methods and Techniques, Federal University of Santa Maria, Santa Maria, Brazil
| | - N. Schweinfurth
- grid.6612.30000 0004 1937 0642University of Basel, Psychiatric Clinics, Center for Affective, Stress and Sleep Disorders, Basel, Switzerland
| | - B. Stubbs
- grid.13097.3c0000 0001 2322 6764Department of Psychological Medicine, King’s College London, London, England
| | - R. Uwakwe
- grid.412207.20000 0001 0117 5863Faculty of Medicine, Nnamdi Azikiwe University, Awka, Nigeria
| | - T. Van Damme
- grid.5596.f0000 0001 0668 7884Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium
| | - E. Van Der Stouwe
- grid.4494.d0000 0000 9558 4598University of Groningen, University Medical Center Groningen, University Center of Psychiatry, Groningen, Netherlands
| | - D. Vancampfort
- grid.5596.f0000 0001 0668 7884Department of Rehabilitation Sciences, KU Leuven, Leuven, Belgium
| | - S. Vetter
- grid.7400.30000 0004 1937 0650Department of Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland
| | - A. Waterreus
- grid.1012.20000 0004 1936 7910Neuropsychiatric Epidemiology Research Unit, School of Population and Global Health, University of Western Australia, Perth, Australia
| | - P. B. Ward
- grid.1005.40000 0004 4902 0432School of Psychiatry, UNSW Sydney, Sydney, Australia ,grid.429098.eSchizophrenia Research Unit, Ingham Institute of Applied Medical Research, Liverpool, Australia
| |
Collapse
|
26
|
Sato J, Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Shimomura A, Tamura K, Iwasa S, Kondo S, Sudo K, Ikezawa H, Nomoto M, Nakajima R, Miura T, Yamamoto N. 17O A first-in-human phase I study of MORAb-202 in patients with folate receptor alpha-positive advanced solid tumors. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.01.026] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
27
|
Kondo S, Matsuura S, Ariunbold J, Kinoshita Y, Urushihara M, Suga K, Ozaki N, Nagai T, Fujioka K, Kagami S. Expression of NADPH oxidase and production of reactive oxygen species contribute to ureteric bud branching and nephrogenesis. J Med Invest 2019; 66:93-98. [PMID: 31064963 DOI: 10.2152/jmi.66.93] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Ureteric bud branching and nephrogenesis are performed through large-scale proliferation and apoptosis events during renal development. Reactive oxygen species (ROS), produced by NADPH oxidase, may contribute to cell behaviors, including proliferation and apoptosis. We investigated the role of NADPH oxidase expression and ROS production in developing kidneys. Immunohistochemistry revealed that NADPH oxidase componentswere expressed on epithelial cells in ureteric bud branches, as well as on immature glomerular cells and epithelial cells in nephrogenic zones. ROS production, detected by dihydroethidium assay, was strongly observed in ureteric bud branches and nephrogenic zones, corresponding with NADPH oxidase localization. Organ culture of E14 kidneys revealed that the inhibition of NADPH oxidase significantly reduced the number of ureteric bud branches and tips, consistent with reduced ROS production. This was associated with reduced expression of phosphorylated ERK1/2 and increased expression of cleaved caspase-3. Organ culture of E18 kidneys showed that the inhibition of NADPH oxidase reduced nephrogenic zone size, accompanied by reduced ROS production, fewer proliferating cell nuclear antigen-positive cells, lower p-ERK1/2 expression, and increased expression of cleaved caspase-3. These results demonstrate that ROS produced by NADPH oxidase might play an important role in ureteric bud branching and nephrogenesis by regulating proliferation and apoptosis. J.Med. Invest. 66 :93-98, February, 2019.
Collapse
Affiliation(s)
- Shuji Kondo
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Sato Matsuura
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Jamba Ariunbold
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Yukiko Kinoshita
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Maki Urushihara
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Kenichi Suga
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Natsuko Ozaki
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Takashi Nagai
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Keisuke Fujioka
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| | - Shoji Kagami
- Department of Pediatrics, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima, Japan
| |
Collapse
|
28
|
Kuriya K, Nishio M, Ono N, Masuda Y, Katsuzaki H, Kondo S, Sono J, Nakamura M, Umekawa H. Isolation and Characterization of Antihyperglycemic Compounds from Vigna angularis Extracts. J Food Sci 2019; 84:3172-3178. [PMID: 31613007 DOI: 10.1111/1750-3841.14840] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 08/29/2019] [Accepted: 09/13/2019] [Indexed: 11/28/2022]
Abstract
Functional foods that inhibit α-amylase and α-glucosidase activity are effective for regulating the blood glucose level and preventing hyperglycemia. Extracts of adzuki beans (ABs, Vigna angularis), widely eaten in East Asia, can inhibit α-amylase and α-glucosidase activity. In this study, we identified and evaluated the components in an AB water extract (ABWE) after boiling, which is an essential process for cooking ABs. The ABWE before boiling inhibited α-amylase and α-glucosidase activity and the boiled ABWE showed slightly stronger inhibitory effects. High-performance liquid chromatography, liquid chromatography-mass spectrometry, and nuclear magnetic resonance analyses identified (+)-catechin 7-O-β-d-glucopyranoside (C7G), (+)-epicatechin 7-O-β-d-glucopyranoside (E7G), and (+)-catechin as the bioactive components in boiled ABWE. Interestingly, the quantity of E7G significantly increased after boiling (from 0% to 17.1 ± 1.3%). E7G showed stronger inhibition of α-amylase and α-glucosidase than C7G; the IC50 values for α-amylase were 0.74 ± 0.04 mg/mL (C7G) and 0.40 ± 0.09 mg/mL (E7G), and for α-glucosidase the IC50 values were 0.085 ± 0.032 mg/mL (C7G) and 0.051 ± 0.007 mg/mL (E7G). Our findings suggest that C7G and E7G are the main active components in ABWE as they inhibit α-amylase and α-glucosidase and their inhibitory effect is not lost after boiling. These results support the effectiveness of boiled ABs in the promotion of health. PRACTICAL APPLICATION: We identified (+)-catechin 7-O-β-d-glucopyranoside (C7G), (+)-epicatechin 7-O-β-d-glucopyranoside (E7G), and (+)-catechin in adzuki bean extracts and commercially available boiled adzuki bean products. Interestingly, the E7G content was increased by boiling, and this compound showed strong inhibitory activity toward α-amylase and α-glucosidase. These results support the consumption of boiled adzuki beans to prevent acute rises in blood glucose level.
Collapse
Affiliation(s)
- Kenji Kuriya
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| | - Masahiro Nishio
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| | - Nanako Ono
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| | - Yuichi Masuda
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| | - Hirotaka Katsuzaki
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| | - Shuji Kondo
- Imuraya Co. Ltd., 7-1-1 Takachaya, Tsu, Mie 514-8530, Japan
| | - Junpei Sono
- Imuraya Co. Ltd., 7-1-1 Takachaya, Tsu, Mie 514-8530, Japan
| | | | - Hayato Umekawa
- Dept. of Life Sciences, Graduate School of Bioresources, Mie Univ., 1577 Kurimamachiya, Tsu, Mie 514-8507, Japan
| |
Collapse
|
29
|
Kondo S, Maruki Y, Hosoi H. Estimation of HPQ-based absenteeism and presenteeism in cancer patients via ResearchKit. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz274.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Yamamoto N, Sato J, Koyama T, Iwasa S, Shimomura A, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Tamura K, Suzuki T, Takase T, Nishiwaki Y, Nakai K, Shimizu T. Phase I study of liposomal formulation of eribulin (E7389-LF) in patients (pts) with advanced solid tumours: Primary results of dose-escalation part. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.043] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Itani H, Nigi A, Iwamoto K, Ito Y, Tanigawa M, Kondo S. P2.01-59 PD-L1 Very High Expression Associated with Clinical Outcome of Pembrolizumab Monotherapy of Advanced NSCLC with PD-L1 TPS of 50% or Greater. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
32
|
Tohgasaki T, Kondo S, Nishizawa S, Suzuki T, Ishiwatari S, Matsukuma S, Ishikawa S, Takeda A. 317 EMILIN-1 is important for age-related changes in elastic fibre structure. J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.07.318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
33
|
Takahashi T, Yamano T, Nishimura K, Ueno S, Washizu K, Soda R, Kondo S, Utsumi N, Shimbo M, Hatanaka S, Hariu M. PO-0752 Hypofractionated stereotactic radiotherapy for inoperable arteriovenous malformations. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31172-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
34
|
Sato J, Itahashi K, Shimizu T, Koyama T, Kondo S, Fujiwara Y, Yamamoto N. Dynamic change in the distribution of cancer types in oncology phase I trials. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz026.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
35
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy432.005] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Kitano S, Shimizu T, Koyama T, Ebata T, Iwasa S, Kondo S, Shimomura A, Fujiwara Y, Yamamoto N, Baum C, Li S, Rietschel P, Sims T. A phase I trial of the safety and pharmacokinetics of cemiplimab, a human monoclonal antibody to programmed death-1, in Japanese patients with advanced malignancies, including expansion cohorts for patients with non-small-cell lung cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy430.013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Yamamoto N, Fujiwara Y, Kondo S, Iwasa S, Yonemori K, Shimomura A, Kitano S, Shimizu T, Koyama T, Ebata T, Sato N, Nakai K, Inatani M, Tamura K. Phase I study of IDO1 inhibitor navoximod (GDC-0919) as monotherapy and in combination with atezolizumab in Japanese patients with advanced solid tumors. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy279.411] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
38
|
Bang YJ, Doi T, Kondo S, Chung H, Muro K, Dussault I, Helwig C, Osada M, Kang YK. Updated results from a phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with pretreated recurrent or refractory gastric cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.045] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
39
|
Lin CC, Doi T, Muro K, Hou MM, Esaki T, Hara H, Chung HC, Osada M, Helwig C, Kondo S. Phase I study results from an esophageal squamous cell carcinoma (ESCC) cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor β (TGF-β) and PD-L1. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Yoo C, Oh DY, Choi H, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M. M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy282.140] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Enomoto Y, Nakatani H, Kondo S, Kasai T, Tsuchiya Y. Drug-induced oral lichenoid reaction during nivolumab therapy. Int J Oral Maxillofac Surg 2018; 48:488-491. [PMID: 30170775 DOI: 10.1016/j.ijom.2018.07.025] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2018] [Revised: 05/14/2018] [Accepted: 07/17/2018] [Indexed: 11/19/2022]
Abstract
Oral lichenoid reaction, an immune-related adverse event of immunotherapy, has been reported in very few patients receiving anti-programmed cell death receptor-1 (anti-PD-1) therapy. Here, we describe a case of severe stomatitis (grade ≥3 by the Common Terminology Criteria for Adverse Events, version 4.0) accompanied by pharyngolaryngitis that was observed in a patient receiving nivolumab therapy. The stomatitis was diagnosed as drug-induced lichenoid reaction. Nivolumab therapy was discontinued, and the patient was administered systemic prednisolone (1mg/kg). Most of the patient's mucosal changes in the oral cavity and pharyngolarynx resolved within approximately 3 weeks after starting the prednisolone. Clinicians should be aware that severe oral lichenoid reactions can occur in patients receiving anti-PD-1 therapy.
Collapse
Affiliation(s)
- Y Enomoto
- Department of Oral and Maxillofacial Surgery, Tochigi Cancer Center, Japan.
| | - H Nakatani
- Department of Otolaryngology, Head and Neck Surgery, National Hospital Organization Fukuyama Medical Center, Japan
| | - S Kondo
- Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Fukuoka University, Japan
| | - T Kasai
- Department of Medical Oncology, Division of Thoracic Oncology, Tochigi Cancer Center, Japan
| | - Y Tsuchiya
- Department of Oral and Maxillofacial Surgery, Tochigi Cancer Center, Japan
| |
Collapse
|
42
|
Kondo T, Yamada S, Okumura T, Kazama S, Ishihara T, Shimojo M, Iwata E, Kondo S, Hiraiwa H, Tanimura D, Kato T, Awaji Y, Murohara T. P4485Haemodynamic and electrical safety of neuromuscular electrical stimulation in acute decompensated heart failure. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.p4485] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- T Kondo
- Nagoya University Graduate School of Medicine, Department of Cardiology, Nagoya, Japan
| | - S Yamada
- Nagoya University Graduate School of Medicine, Rehabilitation of Medical Science, Nagoya, Japan
| | - T Okumura
- Nagoya University Graduate School of Medicine, Department of Cardiology, Nagoya, Japan
| | - S Kazama
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - T Ishihara
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - M Shimojo
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - E Iwata
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - S Kondo
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - H Hiraiwa
- Nagoya University Graduate School of Medicine, Department of Cardiology, Nagoya, Japan
| | - D Tanimura
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - T Kato
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - Y Awaji
- Nagoya Ekisaikai Hospital, Department of Cardiology, Nagoya, Japan
| | - T Murohara
- Nagoya University Graduate School of Medicine, Department of Cardiology, Nagoya, Japan
| |
Collapse
|
43
|
Koyama T, Kondo S, Shimizu T, Fujiwara Y, Kitano S, Ebata T, Shimomura A, Morizane C, Okusaka T, Yamamoto N. Impact of chronic hepatitis virus infection on the feasibility and efficacy for Asian patients with hepatocellular carcinoma in phase I clinical trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
44
|
Shimomura A, Ebata T, Koyama T, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Shimizu T, Yamamoto N. Comparison of model-based dose escalation design with rule-based design of phase I oncology trials. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
45
|
Ebata T, Shimomura A, Koyama T, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Shimizu T, Yamamoto N. Impact by age on dose-limiting toxicities in phase 1 oncology trials of cytotoxic agents and molecular targeted agents. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy047.061] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kuboi T, Miyagi M, Kondo S, Arioka M, Yamato S, Sadamura T, Jinnai W, Nakano A, Ota A. Congenital abdominal aortic aneurysm discovered incidental to a lower back mass. Pediatr Int 2018; 60:98-99. [PMID: 29356288 DOI: 10.1111/ped.13458] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2017] [Revised: 08/07/2017] [Accepted: 10/10/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Toru Kuboi
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Megumi Miyagi
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Shuji Kondo
- Department of Pediatrics, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Makoto Arioka
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Satoshi Yamato
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Takaaki Sadamura
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Wataru Jinnai
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Akiko Nakano
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| | - Akira Ota
- Departments of Neonatology, Shikoku Medical Center for Children and Adults, Kagawa, Japan
| |
Collapse
|
47
|
Ebata T, Shimizu T, Iizumi S, Koyama T, Shimomura A, Iwasa S, Kondo S, Kitano S, Yonemori K, Fujiwara Y, Yamamoto N. Prognostic factors of patients received immunocheckpoint inhibitors in oncology phase 1 trials. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx658.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
48
|
Itani H, Iwamoto K, Ito Y, Sasano H, Kondo S, Tanigawa M. P3.01-064 Detection of EGFR Mutations in Circulating Tumor DNA Using Plasma Samples: Clinical Validation of Cobas EGFR Mutation Test V2. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1505] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
49
|
Kamogawa K, Ninomiya S, Watanabe M, Kondo S, Matsumoto Y, Tomita H, Okamoto K, Okuda B. Cheiro-Oral syndrome from lateral medullary infarction. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
50
|
Watanabe M, Ninomiya S, Kondo S, Matsumoto Y, Kamogawa K, Tomita H, Okamoto K, Okuda B, Mizuta I, Mizuno T. Clinical variety of two cases of hereditary sensory and autonomic neuropathy type 1E with cognitive disorders. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|